期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

预测乳腺癌治疗中蒽环类药物疗效的分子生物学标志物 被引量：2

在线阅读 下载PDF
导出
摘要 蒽环类药物被广泛应用于人类乳腺癌的治疗,患者不同,疗效也不尽相同。目前,对此尚缺乏可靠的疗效预测指标。有研究提示,人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)及拓扑异构酶ⅡA(topoisomeⅡA,TOP2A)基因的表达量提高和(或)其蛋白过表达与肿瘤对蒽环类药物的疗效有关,蒽环类药物对HER2和(或)TOP2A表达为阳性的肿瘤疗效较好。其次,乳腺癌易感基因BRCA1编码的蛋白可修复损伤的DNA,因此BRCA1基因突变的患者对蒽环类药物可能有良好的反应。
作者 吴佳毅 沈坤炜
机构地区 复旦大学附属肿瘤医院乳腺外科
出处 《肿瘤》 CAS CSCD 北大核心 2009年第3期289-294,共6页 Tumor
关键词 乳腺肿瘤 蒽类 抗肿瘤联合化疗方案 Meta分析 基因 HER2 基因 TOP2A
分类号 R737.9 [医药卫生—肿瘤]
作者简介 吴佳毅(1983-),男,(汉族),硕士研究生;Correspondence to:沈坤炜,E-mail:kwshen@medmail.com.cn
  • 相关文献

参考文献30

  • 1PAIK S, BRYANT J, PARK C, et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node positive, hormone receptor negative breast cancer[J]. J Natl Cancer lnst, 1998,90 (18) :1361-1370.
  • 2DE PLACIDO S, PERRONE F, CARLOMAGNO C, et al. CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomized clinical trial ( Naples GUN-3 Study) [ J]. Br J Cancer, 1995,71 (6) : 1283-1287.
  • 3PR|TCHARD K I, SHEPHERD L E, O' MALLEY F P, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy [J]. N Engl J Med,2006,354(20) :2103-2111.
  • 4VERA R, ALBANELL J, LIROLA JL, et al. HER2 overexpression as a predictor of survival in a trial comparing adjuvant FAC and C MF in breast cancer[ J ]. Proc Am Soc Clin Oncol, 1999,18: abstr 265.
  • 5PAIK S, BRYANT J, TAN-CHIU E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgi- cal Adjuvant Breast and Bowel Project Protocol B-15 [ J]. J Natl Cancer lnst,2000,92 ( 24 ) : 1991-1998.
  • 6PETRUZELKA L, PRIBYLOVA O, VEDRALOVA J, et al.C-erbB-2 overexpression and treatment outcome in a randomized trial comparing adjuvant CMF and AC in equitoxic regimen in breast cancer[ J]. Pro Am Soc Clin Oncol,2000,19 : abstr 534.
  • 7DI LEO A, LARSIMONT D, GANCBERG D, et al. HER2 and topo-isomerase Ⅱ alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclopbospbamide[J]. Ann Oncol,2001, 12(8) : 1081-1089.
  • 8DI LEO A, GANCBERG D, LARSIMONT D, et al. HER2 amplification and topoisomerase Ⅱ alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil [ J ]. Clin Cancer Res, 2002,8(5) :1107-1116.
  • 9MOLITERNI A, MENARD S,VALAGUSSA P,et al. HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer[ J]. J Clin 0ncol,2003,21 (3) :458-462.
  • 10COLOZZA M, SIDONI A, MOSCONI A M, et al, HER2 over-expression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/ methotrexate/5-fluorouraeil with epirubicin in patients with stage Ⅰ / Ⅱbreast cancer: Long-term resuits[J]. Clini Breast Cancer,2005,6(3) :253-259.

同被引文献14

  • 1司徒红林,张蓉,陈前军.蒽环类化疗药物在治疗乳腺癌中的应用[J].广东医学,2006,27(10):1579-1581. 被引量：2
  • 2Puglisi F, Minisini A, De Angelis C, et al. Overcoming treatment resistance in HER2- positive breast cancer: potential strategies[J]. Drugs, 2012, 72(9):11 75-1193.
  • 3Xia W, Bacus S, Hegde P, et al. A model of required autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer[J]. Proc Natl Acad Sci U S A, 2006, 103(20):7795-7800.
  • 4Liu L, Greger J, Shi H, of lapatinib resistance et al. Novel mechanism in HER2-positive breast tumor cells: activation of AXL[J]. Cancer Res 2009, 69(17):6871-6878.
  • 5Huang C, Park C, Hilsenbeck S, et al. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib[J]. Breast Cancer Res, 2011, 13(4):R84.
  • 6Jegg A, Ward TM, Iorns E, et al. PI3K independent activation of mTORC1 as a target in lapatinib- resistant ERBB2+ breast cancer cells[J]. Breast Cancer Res Treat, 2012, 136(3):683-692.
  • 7Brady S, Zhang J, Seok D, et al. Enhanced PI3K p110α signaling confers acquired lapatinib resistance which can be effectively reversed by a p110α-selective PI3K inhibitor[J]. Mol Cancer Ther, 2014, 13(1 ):60-70.
  • 8马传栋,沈坤炜,沈镇宙.拉帕替尼治疗乳腺癌的研究进展[J].中华肿瘤杂志,2008,30(5):321-324. 被引量：9
  • 9王琪,姚静静,蒋荷,朱兰,程时丹,王立夫.Smad4静默前后PanIN细胞基因芯片检测及表达谱的研究[J].中国癌症杂志,2011,21(1):1-5. 被引量：1
  • 10李宏江.乳腺癌的治疗现状[J].华西医学,2011,26(7):961-964. 被引量：17

引证文献2

二级引证文献2

肿瘤
2009年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
关于我们 | 版权声明 | 联系我们 | 帮助中心| 意见反馈
主办单位：上海市教育委员会
技术支持：重庆维普资讯有限公司
渝公网安备 50019002500403号
使用帮助 返回顶部